Reneo Pharmaceuticals

OnKure Therapeutics Advances Mutant-Specific PI3Kα Inhibitor OKI-219 Following Merger

• OnKure Inc. and Reneo Pharmaceuticals have completed a merger, resulting in OnKure Therapeutics, which now trades on the Nasdaq under the ticker symbol 'OKUR'. • The merger includes a $65 million private placement to support the clinical development of OnKure's drug pipeline, extending the company's cash runway into Q4 2026. • OnKure's lead drug candidate, OKI-219, a selective PI3Kα H1047R inhibitor, is currently in Phase I clinical trials for solid tumors, including breast cancer. • The combined company will focus on exploiting vulnerabilities in PI3K-mutated cancers, with early clinical data for OKI-219 expected later this year.